CollPlant (CLGN) Biotechnologies announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant’s injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively. This newly allowed patent application pertains to CollPlant’s injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development. The European Patent Application is directed, among other things, to a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler within it, each based on its recombinant human collagen.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLGN:
- CollPlant Biotechnologies Announces $3.6 Million Securities Offering
- CollPlant Biotechnologies Secures $3.6 Million in Direct Offering
- CollPlant to sell 1.2M ordinary shares at $3.00 in registered direct offering
- CollPlant Biotechnologies Reports Strong Q1 2025 Results
- CollPlant Biotechnologies Announces Q1 2025 Financial Results and Corporate Progress